{"id":"chadox1-ncov-19-two-dose-paracetamol","safety":{"commonSideEffects":[{"rate":"~50","effect":"Injection site pain"},{"rate":"~40","effect":"Fatigue"},{"rate":"~35","effect":"Headache"},{"rate":"~30","effect":"Myalgia"},{"rate":"~20","effect":"Fever"},{"rate":"~15","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to carry genetic instructions for the SARS-CoV-2 spike protein into host cells. This triggers both cellular and humoral immune responses, generating T-cell and antibody-mediated immunity against the virus. Paracetamol is co-administered as an antipyretic/analgesic to manage common post-vaccination symptoms.","oneSentence":"ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:28.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults (Phase 3)"}]},"trialDetails":[{"nctId":"NCT04324606","phase":"PHASE1, PHASE2","title":"A Study of a Candidate COVID-19 Vaccine (COV001)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-04-23","conditions":"Coronavirus","enrollment":1077},{"nctId":"NCT04536051","phase":"PHASE3","title":"A Study of a Candidate COVID-19 Vaccine (COV003)","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2020-06-02","conditions":"Coronavirus","enrollment":10300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ChAdOx1 nCoV-19 two dose + paracetamol","genericName":"ChAdOx1 nCoV-19 two dose + paracetamol","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Biologic","firstApprovalDate":"","aiSummary":"ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19. Used for COVID-19 prevention in adults (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}